Business Wire Feed
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant more...
Children’s Hospital Los Angeles Celebrates 125 Years: From One Doctor on Horseback to Global Pediatric Leader
Top 10 pediatric hospital honors a legacy of innovation, compassion, and breakthroughs shaping the future of pediatric medicineLOS ANGELES--(BUSINESS WIRE)--Children’s Hospital Los Angeles (CHLA) is marking its 125th anniversary, celebrating more than a century of more...
Herbalife to Announce First Quarter 2026 Results on May 6
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, will release its first quarter 2026 financial results after the close of trading on the NYSE on Wednesday, May 6, more...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of more...
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
International partnerships and expanded IP coverage accelerate global adoption of Amprion’s alpha-synuclein seed amplification technologySAN FRANCISCO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a series of strategic more...
Bruker Announces Appointment of Thierry Bernard to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics more...
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan more...
Novocure to Report First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 more...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million Simultaneously conversion of $25 million of the outstanding promissory note more...
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma
– Enrollment underway in UK and U.S. for initial registration-supporting study; first patient dosed at The Royal Marsden NHS Foundation Trust in London – – InoPd with inobrodib 20 mg previously demonstrated response rates at more...
CapVest Completes Majority Acquisition of Stada
BAD VILBEL, Germany & LONDON--(BUSINESS WIRE)--CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading more...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating more...
AI Med Consult and 4D EMR Announce Strategic Partnership to Advance AI-Driven Patient Engagement and Practice Efficiency
TAMPA, Fla.--(BUSINESS WIRE)--AI Med Consult and 4th Dimension EMR officially announced a strategic partnership during the American Academy of Cosmetic Surgery (AACS) Annual Scientific Meeting in Tampa, unveiling a collaboration designed to improve patient engagement, more...
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meeting FDA and Novo Nordisk Q1 2026 interactions resulted more...
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023 The 3-year total prevalence of GAD reached 10.3%, representing more than 1 in 10 U.S. adultsNEW more...
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma carePRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Myeloma--Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, more...
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform
Round Led by Collaborative Fund with Participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Cristiano Ronaldo, LeBron James, Rory McIlroyBOSTON--(BUSINESS WIRE)--WHOOP, the human performance company, today announced it has more...
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Prospective study published in Clinical Cancer Research shows that women >70 who tested Signatera MRD-negative could avoid surgery and remain progression-freeAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, more...
Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis Clinic
Voted best by Toronto Star Readers’ Choice AwardsSMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that its Apollo Cannabis Clinics (“Apollo”) has been named Best Medical more...
Sol-Millennium Medical Inc. Launches U.S. B2B eShop, Providing Direct Access to Safety Engineered Medical Devices Nationwide
CHICAGO--(BUSINESS WIRE)--#B2B--Sol-Millennium Medical Inc., a global medical device company focused on patient safety, clinical efficiency, and healthcare outcomes, today announced the launch of its dedicated U.S. B2B e commerce platform, b2b.solm.com. The new platform enables more...
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The more...
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
PREVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly progressive participants The design of the potentially registrational more...
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
BEIJING & TOKYO--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has more...
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing more...
Advanced eClinical Training Partners with Emory University’s HeartStart Program to Deliver Medical Assistant Training for Pre-Medical Students
NEW YORK--(BUSINESS WIRE)--Advanced eClinical Training (ACT) has announced a partnership with the HeartStart program at Emory University to deliver a customized Clinical Medical Assistant (CCMA) training program for pre-medical students. This initiative is designed to more...